Goodwin’s Life Sciences team advised Medicxi Ventures as they closed a $22.5 million Series A financing round with Impact Biomedicines. Impact Biomedicines will use the funds to launch the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. The company’s pipeline is centered around fedratinib, a potent and highly selective oral small molecule.
Medicxi Ventures manages the legacy life science portfolio of Index Ventures as well as the newly launched Medicxi 1 (MV1) and Medicxi Growth 1 (MG1) funds, which focus on investing in early stage and late-stage life sciences opportunities, respectively.
For additional details on the financing, please read the press release.